Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Boston based CFO’ operating in the Health Care space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chuck Carelli
CFO of Flagship Pioneering
Chuck Carelli, CPA, joined Flagship Ventures in 2009 with 16 years of experience in financial accounting, reporting and management. After obtaining his CPA license while working in the Boston office of Deloitte & Touche, Chuck spent 13 years in various senior financial accounting and management roles at three Massachusetts-based publicly traded biotech companies. From 2004 until joining Flagship, he served in various senior financial roles with EXACT Sciences, most recently as Chief Financial Officer. Previously he was with Alkermes, Inc. serving first as Controller then as Director of Finance. He also served as Accounting Manager and then Director of Accounting at Creative BioMolecules. As CFO, Chuck is responsible for all of Flagship Ventures’ financial and tax reporting, cash flow management, fund audits, and financial administration, as well as the financial operations of Flagship’s VentureLabsTM unit. Chuck holds a BA in Accounting from Assumption College.
Follow Chuck Carelli:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Sravan K. Emany
SVP & Chief Financial Officer of Ironwood Pharmaceuticals
Sravan K. Emany is Chief Financial Officer at Ironwood. Before joining the company in 2021, Mr. Emany served as the Corporate Vice President, Commercial Excellence and Chief Strategy Officer at Integra Lifesciences Holdings Corporation, where he was responsible for the Company’s commercial support functions and led the development of their corporate strategy. Prior to Integra, Mr. Emany was at Bank of America for ten years and held roles of increasing responsibility within the Mergers & Acquisitions (M&A) business, ultimately serving as a Managing Director of the M&A group. Mr. Emany began his career working at several well-respected banking institutions including Morgan Stanley and Goldman Sachs. Mr. Emany has a B.A. in international relations and an M.A. in international relations and international economics, both from Johns Hopkins University.
Follow Sravan K. Emany:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Jeanne Henry
CFO of Excel Venture Management
Jeanne joined the Excel team in 2009 and brings more than 18 years of venture capital financial management and reporting experience to the team. Previously, Jeanne was CFO and most recently COO with Atlas Venture, an international venture firm. Earlier she was an Audit Manager with Coopers & Lybrand (now PricewaterhouseCoopers). Jeanne holds a B.A. from the University of New Hampshire, an MBA from the University of Illinois, Chicago and is a Certified Public Accountant. She is a member of the AICPA, the M.A. Society of CPA’s, and a former Board member of the Private Equity CFO Association.
Follow Jeanne Henry:
About Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Kevin Gillis
CFO / Partner of Third Rock Ventures
Kevin Gillis joined Third Rock Ventures in 2008 and oversees the operational, financial and administrative aspects of the firm. He also directs and oversees the initial operational activities for our portfolio companies. Kevin has approximately 20 years of financial experience, successfully designing, overseeing and managing the financial operations for both newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Kevin was Vice President of Finance at Coley Pharmaceutical Group, supporting the company’s successful initial public offering in 2005 and overseeing the finances related to the company’s acquisition by Pfizer in 2008. Prior to Coley, Kevin served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company. Kevin holds an MBA from Bentley University and a BA from Brandeis University.
Follow Kevin Gillis:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Ommer Chohan
Chief Financial Officer of Atlas Venture
Ommer Chohan joined Atlas in 2015 and servers as the firm’s Chief Financial Officer. He oversees the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was CFO/COO at Summerhill Venture Partners. Ommer joined Summerhill in 2006 and was part of the original team that spun out the firm from Bell Canada. At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team. Prior to Summerhill, Ommer was the VP-Finance at First Asset Management Inc. (acquired by Affiliated Managers Group), a holding company with equity interests in several leading Canadian asset management firms. Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.
Follow Ommer Chohan:
About Atlas Venture: Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Dan Tempesta
Chief Financial Officer and EVP of Nuance Communications
Dan Tempesta assumed the role of executive vice president and Chief Financial Officer of Nuance in July 2015. Since joining Nuance in 2008, Dan has held several senior finance roles, having most recently served as Nuance’s Chief Accounting Officer, Corporate Controller, and Senior Vice President of Finance. Dan brings more than 20 years of experience to the role, including extensive financial and operational experience with publicly-held companies and accounting firms. During his time at Nuance, Dan has led the majority of Nuance’s finance and accounting operations, as well as tax, treasury, order management, and internal control activities. He received an accounting degree from the Isenberg School of Management at the University of Massachusetts, Amherst.
Follow Dan Tempesta:
About Nuance Communications: Nuance Communications provides conversational AI innovations that bring intelligence to everyday work and life.
Peter Aranow
Chief Financial Officer of Respiratory Motion
Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Follow Peter Aranow:
About Harvard Business School Community Action Partners, Off Track Betting New York, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
John Withee
CFO of New Balance
Mr. John Withee has been Chief Financial Officer and Executive Vice President of New Balance Athletic Shoe, Inc. since February 2005. Mr. Withee began his career with New Balance as the Manufacturing Controller in 1989. During his tenure he has been instrumental in guiding business during substantial growth periods and he continues to counsel in both the financial and the operational aspects of the business. He holds a Bachelor of Science from the University of Maine
Follow John Withee:
About New Balance: New Balance is an American multinational corporation based in the Brighton neighborhood of Boston.
Daniel Geffken
Interim Chief Financial Officer of CalciMedica
Daniel E. Geffken is the founder and managing director of Danforth Advisors, a consulting firm providing administrative, strategic and operational support to life science companies. He has more than 20 years of experience in the life science industry, with companies ranging from early startups to publicly-traded companies with over $1 billion market capitalizations. Previously, he served as chief operating officer or chief financial officer of four publicly-traded and four privately-held companies, in addition to his consulting clients, and was interim chief executive officer of a medical device company. In these roles, he held management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property and manufacturing functions. Mr. Geffken has raised more than $700 million in equity and debt securities, including a $132 million private placement that was, at the time, the largest private investment in public equity (PIPE) in biotechnology history. Previous to these roles, Mr. Geffken was a principal in a private equity firm, and prior to that position was a certified public accountant (CPA) at KPMG. Mr. Geffken holds a master’s degree in business administration from Harvard Business School and a bachelor’s degree in economics from The Wharton School at the University of Pennsylvania.
Follow Daniel Geffken:
About AnTolRx, Apic Bio, CalciMedica, Danforth Advisors, Danforth Diamond, DermBiont, Elicio Therapeutics, ProMIS Neurosciences, Vigeo Therapeutics, Zikani Therapeutics: CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Gaurav Agarwal
Chief Financial Officer of emids
Gaurav is in charge of overseeing the company’s finance, legal and secretarial functions.He is an expert in Mergers & Acquisitions, Finance, Investor Relations, Negotiation, Financial analysis, and other related areas. Gaurav works closely with all other executives to build long term and short term strategy and help implement them while adopting the best standards in financial and operational discipline. He is a Chartered Accountant from India and Certified Public Accountant from USA.
Follow Gaurav Agarwal:
About emids: Emids is a consulting firm that provides IT and business process management solutions to the healthcare industry.
Fritz von Mering
Chief Financial Officer of Goodpath
Follow Fritz von Mering:
About Goodpath, Miles River Management: Goodpath is a telehealth startup focused on improve helping people managing common health conditions.
Fred Driscoll
Chief Financial Officer of Flexion Therapeutics
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Fred Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Fred Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Fred Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Follow Fred Driscoll:
About Flexion Therapeutics: Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
David Murray
Chief Financial Officer of Alcon
Follow David Murray:
About Alcon: Alcon specializes in developing and manufacturing innovative medicines and devices to serve the full life cycle of eye care needs.
Mark A. Peters
Chief Financial Officer & Treasurer of Medrobotics
Mark Peters has over 25 years of finance leadership, operations management, business analytics and strategic planning experience in private and public companies, including successful IPO experience. Mr. Peters began his career with PricewaterhouseCoopers and IBM before focusing on high growth medtech companies. His medtech experience includes Chief Financial Officer and Vice President roles for Health Language, a private equity financed healthcare IT company acquired by Wolters Kluwer; IST, a venture funded spinal implant company acquired by Integra LifeSciences; Aura Medsystems, a venture funded tissue closure company founded on technology licensed from Harvard Medical School / Mass. General Hospital; and Seikagaku Corporation, a publicly traded biopharma manufacturer of endotoxin detection re-agents. Mr. Peters earned a BBA in Accounting from The University of Texas and an MBA in Finance from The University of Notre Dame, where he serves as a Director on the Mendoza College of Business Graduate Alumni Board. He previously served on the Board of Directors for MassMEDIC (Massachusetts Medical Device Industry Council) and is a licensed CPA.
Follow Mark A. Peters:
About Medrobotics: Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System.
Will Rousmaniere
Chief Financial Officer of Analogic
Will joined Analogic in 2012 as finance director for the company’s Ultrasound Business. In 2015 he was named senior director, financial planning and analysis. Prior to joining Analogic, Will was director of finance, precision motion and technologies at GSI Group (now Novanta), and held multiple financial leadership roles at Varian Semiconductor Equipment Associates (now a division of Applied Materials) as well as financial and operational roles at a number of technology start-ups. He earned an MBA in finance and accounting from New York University, Stern School of Business, and a BA in Economics from Cornell University and was a Certified Public Accountant.
Follow Will Rousmaniere:
About Analogic: Analogic is a technology company that develops computed tomography, ultrasound, digital mammography, and magnetic resonance imaging systems.
Jeffrey Poulton
Chief Financial Officer of Shire
Jeffrey “Jeff” brings to the Board his financial, commercial and strategic acumen. Since joining Shire in 2003 he has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Follow Jeffrey Poulton:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Genevieve Barnard
CFO & Co-Founder of MDaaS Global
Genevieve Barnard is the CFO and Co- founder of MDaaS. She used to be the associate director of associate director at Kletjian Foundation. Genevieve earned her MBA at Massachusetts Institute of Technology – Sloan School of Management.
Follow Genevieve Barnard:
About MDaaS Global: MDaaS Global operates tech-enabled diagnostic centers in clinically-underserved communities.
Gregory Weaver
Chief Financial Officer of Eloxx
Greg Weaver joined PLI as CFO in November 2015. Greg is an experienced CFO and board director, having served in executive positions with biopharma companies in the US and Europe. Most recently he served as CFO and board director with Oryzon Genomics in Boston and Barcelona, and previously has served as CFO with the following Nasdaq-listed public biotech companies: Fibrocell, Celsion, Poniard, Sirna, Nastech, and ILEX. Greg currently serves on the boards of public biotech companies Egalet, and Atossa Genetics. Greg has led the raise of over US$800 million in various financing transactions throughout his career, and has led companies through IPO, drug development, and revenue growth, while positioning a number of companies for successful acquisition. Greg began his career as a CPA with Arthur Andersen, with an MBA from Boston College and BS in accounting from Trinity University.
Follow Gregory Weaver:
About Eloxx: Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Dan Krzmarzick
CFO of Patientco
Dan Krzmarzick serves as CFO at Patientco.
Follow Dan Krzmarzick:
About Patientco: Patientco improves financial care across the entire patient journey while increasing payments and revenue for today’s top health systems.
Michael Baker
CFO of Cloud 9
Michael Baker is CFO at Cloud9.
Follow Michael Baker:
About Cloud 9: Cloud 9 creates a dual treatment solution for behavioral healthcare prevention and intervention.
Ian C. Sanderson
CFO of Nimbus Therapeutics
Follow Ian C. Sanderson:
About Boston Pharmaceuticals, Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Daniella Beckman
CFO of Tango Therapeutics
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Daniella Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Daniella Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Daniella Beckman also held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers from September 2000 through September 2004. Daniella Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Follow Daniella Beckman:
About Tango Therapeutics: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Bruce Tiedemann
Partner / CFO of Boston Millennia Partners
Bruce is a founder of Tiedemann & Company, an independent certified public accounting firm. He has also served as part-time Chief Financial Officer or Controller of several start-up venture funded companies. His professional experience includes over 20 years of public accounting experience.
Follow Bruce Tiedemann:
About Boston Millennia Partners: Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and business services industries.
Chip Catlin
Senior Vice President and Chief Financial Officer of Celldex Therapeutics
Chip Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Chip Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions adding substantial long term value for the company. Prior to Celldex, Chip Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Chip Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Chip Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him an ideal addition to our board of directors.
Follow Chip Catlin:
About Celldex Therapeutics: Celldex is a clinical stage company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases.
Candice Cantelli Meklis
Chief Financial Officer of PatientsLikeMe
Candice Cantelli Meklis is the Chief Financial Officer at PatientsLikeMe.
Follow Candice Cantelli Meklis:
About PatientsLikeMe: PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform.
Grayson Allen
CFO/COO & Co-Founder of RevBio
Grayson oversees the financial planning and reporting function as Interim CFO at Maxwell Health, and is also involved in strategic and tactical matters related to Maxwell’s continued growth. Previously, Grayson served as the CFO of a venture-backed technology company where he led a team which oversaw all financial planning and reporting, accounting, information technology, and human resources functions at the company. He played a key role in raising more than $60 million in venture capital and implemented the infrastructure necessary for rapid growth. Grayson also served as CFO for a private equity owned company engaged in the design and manufacture of bridge cranes, gantry cranes, and other custom industrial material handling solutions. While there, Grayson played an instrumental role in executing a turnaround strategy which included reducing past due receivables by 71%, managing cash flow during a period of tight liquidity, renegotiating contract terms with customers and suppliers, and assisting in the recapitalization of the ownership structure. Previously, as a Principal at the $500 million private equity arm of a leading commercial bank holding company, he was a member of the team which structured and oversaw a portfolio consisting of private equity, venture capital, and fund-of-funds investments. Grayson started his career as a commercial loan underwriter. Grayson received his B.A. in History (high honors) from Dartmouth College and his M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology. Outside of work, Grayson enjoys being outdoors and active as much as possible, and likes sailing in the summer, hiking in the fall, and running throughout the year. For many years he has collected Asian art and artifacts and has been actively collecting Japanese woodblock prints since he was 12 years old. Both Grayson and his wife Lorraine enjoy cooking together and are always interested in trying out new recipes when they have the chance.
Follow Grayson Allen:
About RevBio: RevBio was started with one goal in mind—to end medicine’s 50-year search for a biocompatible bone adhesive.
Ed Lafferty
General Partner & CFO of Saturn Partners
Follow Ed Lafferty:
About Chirpify, Saturn Partners: Since 1994, Saturn Partners has taken an active role in the formation and management of seed and early-stage technology companies.
Joanne Bryce
Chief Financial Officer of Disc Medicine
Follow Joanne Bryce:
About Disc Medicine, Speedy Packets: Disc Medicine is a hematology company
Spencer Adams
Chief Financial Officer of Docent Health
Spencer Adams is the Chief Financial Officer at Docent Health.
Follow Spencer Adams:
About Docent Health: Helping health systems build and grow lasting patient relationships
Ken Mace
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
William J. Kelly
Chief Financial Officer of Exosome Diagnostics
Mr. Kelly has over 20 years of financial management experience, including 13 years leading growing, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer of RepliGen Corporation and Corporate Controller of Haemonetics. In such roles, Mr. Kelly oversaw corporate financial operations, including several successful acquisitions. Mr. Kelly began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds an M.S./M.B.A. from Northeastern University and a B.A. in psychology from the College of the Holy Cross.
Follow William J. Kelly:
About Deloitte, Exosome Diagnostics: Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring.
Peter E Walcek
Vice President of Finance & Chief Financial Officer of Wentworth-Douglass Hospital
Follow Peter E Walcek:
About Wentworth-Douglass Hospital: Wentworth-Douglass Hospital is a nationally recognized, not-for-profit charitable health care organization.
David A. Frank
Chief Financial Officer of AquaBounty Technologies
Follow David A. Frank:
About AquaBounty Technologies: AquaBounty Technologies is a biotechnology company that focuses on improving productivity in commercial aquaculture.
Gregory Fisichelli
Chief Financial Officer of ZwitterCo
Follow Gregory Fisichelli:
About ZwitterCo: ZwitterCo provides revolutionary membrane solutions for the treatment of highly-impaired wastewater.
Jim Waddell
Chief Financial Officer of Ageless Innovation
Follow Jim Waddell:
About Ageless Innovation: Ageless Innovation is a Health Care company.
Alfonso Hernandez-Maureta
CFO of Sincrolab
Alfonso Hernandez-Maureta is the CFO of SincroLab.
Follow Alfonso Hernandez-Maureta:
About Sincrolab: Sincrolab offers an Artificial Intelligence digital prescription neuro medicine based on videogames delivered through mobile devices.
